Efficacy evaluation of Toll-like receptor (TLR) 7 inhibitor using immune cells derived from connective tissue disease patients

Efficacy evaluation of Toll-like receptor (TLR) 7 inhibitor using immune cells derived from connective tissue disease patients - Efficacy evaluation of Toll-like receptor (TLR) 7 inhibitor using immune cells derived from connective tissue disease patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053738

Enrollment

100

Registered

2024-03-01

Start date

2015-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with systemic lupus erythematosus (SLE) and other connective tissue diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 20-65 years with systemic lupus erythematosus, rheumatoid arthritis, scleroderma, dermatomyositis/polymyositis, Behcet's disease, adult Still's disease, vasculitis syndrome, Sjogren's syndrome, and mixed connective tissue disease attending outpatient clinic of the First Department of Internal Medicine, Toyama University Hospital

Exclusion criteria

Exclusion criteria: Patients with vasculitis that makes blood sampling difficult, patients with allergies to antiseptics

Design outcomes

Primary

Measure	Time frame
To evaluate the responsiveness of peripheral blood mononuclear cells and pDCs derived from collagen disease patients to TLR7 ligand and the efficacy of bacteols compounds to inhibit it, we will evaluate the following two points: SLE patients and non-SLE collagen disease patients will be compared. Protein production: Inflammatory cytokine protein production and chemokine protein production in peripheral blood mononuclear cells and pDC culture supernatants will be measured by ELISA. Gene expression: Peripheral blood monocytes. Gene expression levels: Inflammatory cytokine gene expression, chemokine gene expression and housekeeping gene expression in peripheral blood mononuclear cells and pDC are measured by real-time PCR.	—

Measure

Time frame

To evaluate the responsiveness of peripheral blood mononuclear cells and pDCs derived from collagen disease patients to TLR7 ligand and the efficacy of bacteols compounds to inhibit it, we will evaluate the following two points: SLE patients and non-SLE collagen disease patients will be compared. Protein production: Inflammatory cytokine protein production and chemokine protein production in peripheral blood mononuclear cells and pDC culture supernatants will be measured by ELISA. Gene expression: Peripheral blood monocytes. Gene expression levels: Inflammatory cytokine gene expression, chemokine gene expression and housekeeping gene expression in peripheral blood mononuclear cells and pDC are measured by real-time PCR.

—

Countries

Japan

Contacts

Public ContactKoichiro SHINODA

Toyama University Hospital First Department of Internal Medicine

koichiro@med.u-toyama.ac.jp+81764347287

Outcome results